RenovoRx, Inc.
RNXT· Nasdaq
Released Apr 1, 2024, after the close
10-K filed Apr 1, 2024, 92 days after period end · 0001493152-24-012357
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$3.23M | -$2.16M | -$2.36M | -$878.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2023 · filed Apr 1, 2024 · 92 d after period end
7.5% from the close of Mar 28, 2024 to the close of Apr 3, 2024, the first after the release.